Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B | Q13370 | 2/20 | 0.41 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.37 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.37 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.30 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1414042 | 0.77 | PDE3B (0.41) | PDE3BPDE3ACHRNB2CHRNA4SIGMAR1 | |
| SCHEMBL1398128 | 0.76 | NOS3 (0.39) | PDE3BPDE3ASIGMAR1CYP3A4 | |
| SCHEMBL1105684 | 0.72 | PDE3B (0.39) | PDE3BPDE3ACHRNB2CHRNA4SIGMAR1 | |
| SCHEMBL27628706 | 0.70 | PNMT (0.38) | SIGMAR1 | |
| SCHEMBL20145923 | 0.69 | PDE3B (0.42) | PDE3BPDE3ATDP1 | |
| SCHEMBL3427220 | 0.67 | CHRNB2 (0.42) | PDE3BPDE3ACHRNB2CHRNA4SIGMAR1 | |
| SCHEMBL19699945 | 0.64 | SIGMAR1 (0.39) | PDE3BPDE3ACHRNB2CHRNA4SIGMAR1 | |
| SCHEMBL17811376 | 0.64 | PDE3B (0.36) | PDE3BPDE3ACHRNB2CHRNA4SIGMAR1 | |
| SCHEMBL29419304 | 0.63 | — | — | |
| SCHEMBL28154576 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7531545-B2 | 2-amino-3,4-dihydro-pyrido[3,4-d]pyrimidine derivatives useful as inhibitors of β-secretase (BACE) | JANSSEN PHARMACEUTICA, N.V. (BE) | 2009-05-12 | — | — | US | disclosed |
| US-20070259898-A1 | NOVEL 2-AMINO-3,4-DIHYDRO-PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF beta-SECRETASE (BACE) | BAXTER ELLEN E | 2007-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259898-A1 | NOVEL 2-AMINO-3,4-DIHYDRO-PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF beta-SECRETASE (BACE) | BACE2, PSEN2, BACE1 | PDE3B 2668/4885PDE3A 3005/4885CHRNB2 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.